Altimmune, Inc. (ALT)
NGM · Healthcare · Biotechnology
$2.92
-2.34%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$567.9M
Shares Outstanding
194.5M
P/S (TTM)
15,774x
Exchange
NGM
Currency
USD
About Altimmune, Inc.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 5K | 5K | 26K | 0.00 |
| Operating Income | -22.9M | -20.9M | -28.9M | -24.2M |
| Net Income | -22.1M | -19.0M | -27.4M | -22.6M |
| Diluted EPS | $-0.27 | $-0.21 | $-0.27 | $-0.18 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | -68K | 426K | 20K | 41K |
| Operating Income | -87.7M | -83.5M | -103.2M | -94.5M |
| Net Income | -84.7M | -88.4M | -95.1M | -88.1M |
| Diluted EPS | $-1.81 | $-1.66 | $-1.34 | $-1.00 |